Sanjay Popat, PhD, FRCP, on RET Fusion-Positive NSCLC: First-Line Pralsetinib

May 31, 2026 By The ASCO Post Staff

Sanjay Popat, PhD, FRCP, of the Royal Marsden Hospital & Institute of Cancer Research, talks about the findings of the phase III AcceleRET-Lung study, which looked at the oral tyrosine kinase inhibitor pralsetinib as first-line therapy for patients with RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC) (Abstract 8504).

Related Content